Table 1.
Patient characteristics at baseline
| N=23 | ||
|---|---|---|
| Median age, years (range) | 60 (33-79) | |
| Sex, N (%) | ||
| Male | 12 (52) | |
| Female | 11 (48) | |
| Cytogenetic risks per IMWG, N (%) | ||
| High Risk | 4 (17) | |
| Standard Risk | 19 (83) | |
| ISS stage, N (%) | ||
| I | 17 (74) | |
| II | 5 (22) | |
| III | 1 (4) | |
| Isotype, N (%) | ||
| IgAκ | 3 (13) | |
| IgAλ | 2 (9) | |
| IgGκ | 12 (52) | |
| IgGλ | 2 (9) | |
| Free κ | 3 (13) | |
| Free λ | 1 (4) | |
| SPEP, N (%) | + | 21 (91) |
| − | 2 (9) | |
| Size M-spike, median g/dL (range) | 2.97 (0-8.37) | |
| IFE, N (%) | + | 23 (100) |
| − | 0 (0) | |
| Serum FLC, N (%) | Abnormal | 22 (96) |
| normal | 1 (4) | |
| MALDI-TOF-MS, N (%) | + | 23 (100) |
| − | 0 (0) |
IMWG: International Myeloma Working Group, ISS: International Staging System, FLC: free light chain, SPEP: serum protein electrophoresis, IFE: immunofixation electrophoresis, MALDI-TOF MS: Matrix- assisted laser desorption ionization time of flight mass spectrometry